Last reviewed · How we verify
Org 50081
Org 50081 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.
Org 50081 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects. Used for Muscle wasting or sarcopenia (investigational).
At a glance
| Generic name | Org 50081 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Selective Androgen Receptor Modulator (SARM) |
| Target | Androgen Receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Musculoskeletal / Endocrinology |
| Phase | Phase 3 |
Mechanism of action
As a SARM, Org 50081 selectively activates androgen receptors in muscle and bone tissue, promoting anabolism and potentially improving physical function and muscle mass. Unlike traditional androgens, SARMs are designed to have tissue-selective activity, reducing unwanted androgenic effects in prostate and other tissues. This selectivity profile makes it potentially suitable for conditions requiring anabolic support with a reduced side-effect burden.
Approved indications
- Muscle wasting or sarcopenia (investigational)
Common side effects
- Testosterone suppression
- Headache
- Nausea
Key clinical trials
- Repurposing Mirtazapine in Rett Syndrome (PHASE2)
- Effects of Mirtazapine on Appetite in Advanced Cancer Patients (PHASE2)
- Mirtazapine for Acute and Chronic Post Mastectomy Pain (EARLY_PHASE1)
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Neurobiological and Genomic Predictors of Relapse in Depression
- Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator (EARLY_PHASE1)
- Methamphetamine Use Disorder Support in Heart Failure Pilot Study (NA)
- Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Org 50081 CI brief — competitive landscape report
- Org 50081 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI